Clearmind Medicine Inc. (Nasdaq: CMND) (the "Company"), a clinical-stage biopharmaceutical c

Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination wi

Company Calls for Consideration of New Regulatory Pathways and Cost Saving of Non-Hallucinogenic Neu

learmind Medicine Inc. (the "Company") is announcing that it will effect a reverse share spl

The U.S. patent applications cover proprietary combinations of NeuroThera's PEA technology with LSD,

The covered applications address potential therapeutic uses across a range of indications, including

The covered applications address potential therapeutic uses across a range of indications, including

VANCOUVER, BC September 17, 2026 - TheNewswire — StickIt Technologies Inc. (CSE: STKT) (the "Company

Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and sh

Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “C

Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company" or "Clearmind"), a clinical-sta

Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “C

Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market

Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular se

Shares of Clearmind Medicine Inc. (NASDAQ:CMND) are trading lower Friday morning as investors digest

Clearmind Medicine shares are trading lower Friday as investors weigh the biotech’s move to acquire

Charging Robotics  is one of the few worldwide developing innovative wireless charging systems desig

Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company"), a clinical-stage biopharmaceutical co

Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “C

SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that its  sub

Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biopharmaceutical  company   advancing non-h

U.S. publication of the patent application covering the MDMA-N-acylethanolamines combination expands

U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands i

The independent Data and Safety Monitoring Board on Thursday unanimously approved Clearmind Medicine

Clearmind Medicine advances the CMND-100 clinical trial for alcohol use disorder to Parts B and C fo

Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to adva

Vancouver, Canada, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY

Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to adva

Vancouver, Canada, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearm

Completed treatment as planned per-protocol, reinforcing the strength of its proprietary drug candid

Vancouver, Canada, July 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clini

All 24 participants across cohorts 1 through 4 have successfully completed treatment according to th

Vancouver, Canada, July 28, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“Clearmind” or “Compan

The Hong Kong patent application forms part of Clearmind’s exclusive worldwide licensing agreement w

Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potent

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta

Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage a biotech company developing novel, non-hall

The program is evaluating intranasal delivery of MEAI as a potential additional route of administrat

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta

Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-sta

Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announce